A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Belite Bio, Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 5,211 shares of BLTE stock, worth $318,183. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,211
Previous 6,460 19.33%
Holding current value
$318,183
Previous $302,000 8.61%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$46.52 - $83.84 $58,103 - $104,716
-1,249 Reduced 19.33%
5,211 $328,000
Q3 2024

Nov 14, 2024

BUY
$44.57 - $50.36 $287,922 - $325,325
6,460 New
6,460 $302,000

Others Institutions Holding BLTE

About BELITE BIO, INC


  • Ticker BLTE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,867,400
  • Market Cap $1.52B
  • Description
  • Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...
More about BLTE
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.